Disc Medicine (IRON) moved back into focus after reporting that its pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, alongside encouraging pipeline updates.
Disc Medicine’s share price has picked up momentum recently, with a 1-month share price return of 35.09% and a 90-day gain of 7.54%. However, the 1-year total shareholder return declined 4.28%, while the 3-year total shareholder return is 72.03%.
Scan beyond Disc Medicine and evaluate other hematology and biotech players that screen well on fundamentals through a curated list of 19 high quality undiscovered gems.
Disc Medicine has already rewarded early believers after the APOLLO win, yet the recent jump still leaves a gap between today’s price and what the current valuation implies. How much of the potential is actually reflected in the stock?
Most Popular Narrative: 34% Undervalued
Disc Medicine’s most followed valuation storyline points to a fair value of $125.75 per share versus the last close of $83.28, which highlights a wide gap between what the models indicate and where the stock currently trades.
The numbers on trial response rates, addressable patient pools in EPP and myelofibrosis anemia, and Disc Medicine's current cash runway to 2029 imply a share price that reflects the company as having multiple potential blockbuster assets rather than a single asset story.
See why 1 investors see Disc Medicine as 34% undervalued.
Result: Fair Value of $125.75 (UNDERVALUED)
Still, parts of the Disc Medicine story could break the bullish script if bitopertin faces further FDA delays, or if real world uptake in rare anemia proves slower than analysts model.
Find out about the key risks to this Disc Medicine narrative.
Next Steps
Mixed signals on Disc Medicine so far. If you want a clear view fast, go straight to the underlying data and weigh both the 2 key rewards and 4 important warning signs.
Ready for more Disc Medicine sized ideas?
You have the Disc Medicine story in front of you, but leaving it there risks missing other opportunities that fit your style and risk tolerance.
- Target resilient growth by scanning a curated pool of strong fundamentals and undemanding valuations through the 35 high quality undervalued stocks.
- Prioritize downside protection by filtering for companies with robust finances and clean balance sheets using the list of solid balance sheet and fundamentals (24 results).
- Seek dependable income potential by zeroing in on higher yielding payers with staying power via the 5 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com